Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design

Journal of Virology

Volumn 77, Issue 10, 2003, Pages 5889-5901

  Pantophlet, Ralph ^a   Wilson, Ian A ^a   Burton, Dennis R ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ANTIGEN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN; MONOMERIC IONIC CONTRAST MEDIUM; MUTANT PROTEIN; NEUTRALIZING ANTIBODY;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CHEMICAL MODIFICATION; DRUG DESIGN; GLYCOSYLATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HYPERGLYCOSYLATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MOTIF;

AIDS VACCINES; AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; CELL LINE; DRUG DESIGN; GLYCOSYLATION; HIV ANTIBODIES; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; NEUTRALIZATION TESTS; POLYSACCHARIDES;

EID: 0038414622     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.10.5889-5901.2003     Document Type: Article

References (122)

1. Andre, S., B. Seed, J. Eberle, W. Schraut, A. Bultmann, and J. Haas. 1998. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J. Virol. 72:1497-1503.
2. Arthur, L. O., J. W. Bess, Jr., E. N. Chertova, J. L. Rossio, M. T. Esser, R. E. Benveniste, L. E. Henderson, and J. D. Lifson. 1998. Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. AIDS Res. Hum. Retrovir. 14(Suppl. 3):S311-S319.
3. Back, N. K. T., L. Smit, J.-J. de Jong, W. Keulen, M. Schutten, J. Goudsmit, and M. Tersmette. 1994. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 199:431-438.
4. Barbas, C. F., III, E. Bjorling, F. Chiodi, N. Dunlop, D. Cababa, T. M. Jones, S. L. Zebedee, M. A. Persson, P. L. Nara, E. Norrby, and D. R. Burton. 1992. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. USA 89:9339-9343.
5. Barbas, C. F., III, T. A. Collet, W. Amberg, P. Roben, J. M. Binley, D. Hoekstra, D. Cababa, T. M. Jones, R. A. Williamson, G. R. Pilkington, N. L. Haigwood, E. Cabezas, A. C. Satterthwait, I. Sanz, and D. R. Burton. 1993. Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J. Mol. Biol. 230:812-823.
6. Belshe, R. B., G. J. Gorse, M. J. Mulligan, T. G. Evans, M. C. Keefer, J. L. Excler, A. M. Duliege, J. Tartaglia, W. I. Cox, J. McNamara, K. L. Hwang, A. Bradney, D. Montefiori, and K. J. Weinhold. 1998. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS 12:2407-2415.
7. Bhat, T. N., G. A. Bentley, G. Boulot, M. I. Greene, D. Tello, W. Dall'Acqua, H. Souchon, F. P. Schwarz, R. A. Mariuzza, and R. J. Poljak. 1994. Bound water molecules and conformational stabilization help mediate an antigen-antibody association. Proc. Natl. Acad. Sci. USA 91:1089-1093.
8. Binley, J. M., R. W. Sanders, B. Clas, N. Schuelke, A. Master, Y. Guo, F. Kajumo, D. J. Anselma, P. J. Maddon, W. C. Olson, and J. P. Moore. 2000. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 74:627-643.
9. Binley, J. M., R. W. Sanders, A. Master, C. S. Cayanan, C. L. Wiley, L. Schiffner, B. Travis, S. Kuhmann, D. R. Burton, S.-L. Hu, W. Olson, and J. P. Moore. 2002. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J. Virol. 76:2606-2616.
10. Bolmstedt, A., S. Sjolander, J.-E. S. Hansen, L. Akerblom, A. Hemming, S.-L. Hu, B. Morein, and S. Olofsson. 1996. Influence of N-linked glycans in V4-5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 12:213-220.
11. Braden, B. C., B. A. Fields, and R. J. Poljak. 1995. Conservation of water molecules in an antibody-antigen interaction. J. Mol. Recognit. 8:317-325.
12. Braden, B. C., and R. J. Poljak 1995. Structural features of the reactions between antibodies and protein antigens. FASEB J. 9:9-16.
13. Buchacher, A., R. Predl, K. Strutzenberger, W. Steinfellner, A. Trkola, M. Purtscher, G. Gruber, C. Tauer, F. Steindl, A. Jungbauder, and H. Katinger. 1994. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retrovir. 10:359-369.
14. Buchacher, A., R. Predl, C. Tauer, M. Purtscher, G. Gruber, R. Heider, F. Steindl, A. Trkola, A. Jungbauer, and H. Katinger. 1992. Human monoclonal antibodies against gp41 and gp120 as potential agents for passive immunization, p. 191-194. In F. Brown, R. Chanock, H. S. Ginsberg, and R. Lerner (ed.), Vaccines '92: modern approaches to new vaccines including prevention of AIDS. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
15. Buchbinder, A., S. Karwowska, M. K. Gorny, S. T. Burda, and S. Zolla-Pazner. 1992. Synergy between human monoclonal antibodies to HIV extends their effective biological activity against homologous and divergent strains. AIDS Res. Hum. Retrovir. 8:425-427.
16. Burton, D. R. 1997. A vaccine for HIV type 1: the antibody perspective. Proc. Natl. Acad. Sci. USA 94:10018-10023.
17. Burton, D. R. 2002. Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2:706-713.
18. Burton, D. R., C. F. Barbas III, M. A. A. Persson, S. Koenig, R. M. Chanock, and R. A. Lerner. 1991. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. USA 88:10134-10137.
19. Burton, D. R., J. Pyati, R. Koduri, S. J. Sharp, G. B. Thornton, P. W. H. I. Parren, L. S. W. Sawyer, R. M. Hendry, N. Dunlop, P. L. Nara, M. Lamacchia, E. Garratty, E. R. Stiehm, Y. J. Bryson, Y. Cao, J. P. Moore, D. D. Ho, and C. F. Barbas III. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
20. +-T-cell-depleted rhesus macaques. J. Virol. 75:1547-1550.
21. Chiesa, M. D., P. M. Martensen, C. Simmons, N. Porakishvili, J. Justesen, G. Dougan, I. M. Roitt, P. J. Delves, and T. Lund. 2001. Refocusing of B-cell responses following a single amino acid substitution in an antigen. Immunology 103:172-178.
22. SF2 recombinant gp120, or both vaccines in seronegative adults. J. Infect. Dis. 177:1230-1246.
23. Connor, R. I., B. T. M. Korber, B. S. Graham, B. H. Hahn, D. D. Ho, B. D. Walker, A. U. Neumann, S. H. Vermund, J. Mestecky, S. Jackson, E. Fenamore, Y. Cao, F. Gao, S. Kalams, K. J. Kunstman, D. McDonald, N. McWilliams, A. Trkola, J. P. Moore, and S. M. Wolinsky. 1998. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol. 72:1552-1576.
24. Cummins, L. M., K. J. Weinhold, T. J. Matthews, A. J. Langlois, C. F. Perno, R. M. Condie, and J. P. Allain. 1991. Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors. Blood 77:1111-1117.
25. Davis, D., D. M. Stephens, C. Willers, and P. J. Lachmann. 1990. Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acid sequence within recombinant gp120 of human immunodeficiency virus type 1. J. Gen. Virol. 71:2889-2898.
26. Delves, P. J., T. Lund, and I. M. Roitt. 1997. Can epitope-focused vaccines select advantageous immune responses? Mol. Med. Today 3:55-60.
27. di Marzo Veronese, F. R., R. Rahman, R. Pal, C. Boyer, J. Romano, V. S. Kalyanaraman, B. C. Nair, R. C. Gallo, and M. G. Sarngadharan. 1992. Delineation of immunoreactive, conserved regions in the external envelope glycoprotein of the human immunodeficiency virus type I. AIDS Res. Hum. Retrovir. 8:1125-1132.
28. D'Souza, M. P., D. Livnat, J. A. Bradac, S. Bridges, et al. 1997. Evaluation of monoclonal antibodies to HIV-1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. J. Infect. Dis. 175:1056-1062.
29. Ebenbichler, C., T. McNearney, H. Stoiber, J. Most, R. Zangerle, W. Vogetseder, J. R. Patsch, L. Ratner, and M. P. Dierich. 1995. Sera from HIV-1 infected individuals in all stages of disease preferentially recognize the V3 loop of the prototypic macrophage-tropic glycoprotein gp120 ADA. Mol. Immunol. 32:1039-1045.
30. Finnegan, C. M., W. Berg, G. K. Lewis, and A. L. DeVico. 2001. Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion. J. Virol. 75:11096-11105.
31. Fouts, T. R., J. M. Binley, A. Trkola, J. E. Robinson, and J. P. Moore. 1997. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J. Virol. 71:2779-2785.
32. Fung, M. S. C., C. R. Y. Sun, W. L. Gordon, R.-S. Liou, T. W. Chang, W. N. C. Sun, E. S. Daar, and D. D. Ho. 1992. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J. Virol. 66:848-850.
33. Garrity, R. R., G. Rimmelzwaan, A. Minassian, W.-P. Tsai, G. Lin, J.-J. de Jong, J. Goudsmit, and P. L. Nara. 1997. Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J. Immunol. 159:279-289.
34. Gavel, Y., and G. von Heijne. 1990. Sequence differences between glycosylated and non-glycosylated Asn-X-Thr/Ser acceptor sites: implications for protein engineering. Protein Eng. 3:433-442.
35. Ghiara, J. B., E. A. Stura, R. L. Stanfield, A. T. Profy, and I. A. Wilson. 1994. Crystal structure of the principal neutralization site of HIV-1. Science 264:82-85.
36. Gorny, M. K., A. J. Conley, S. Karwowska, A. Buchbinder, J.-Y. Xu, E. A. Emini, S. Koenig, and S. Zolla-Pazner. 1992. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J. Virol. 66:7538-7542.
37. Gorny, M. K., J. Y. Xu, S. Karwowska, A. Buchbinder, and S. Zolla-Pazner. 1993. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J. Immunol. 150:635-643.
38. Graham, B. S., M. C. Keefer, M. J. McElrath, G. J. Gorse, D. H. Schwartz, K. Weinhold, T. J. Matthews, J. R. Esterlitz, F. Sinangil, P. E. Fast, et al. 1996. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120: a randomized, double-bind trial. Ann. Intern. Med. 125:270-279.
39. Grundner, C., T. Mirzabekov, J. Sodroski, and R. Wyatt. 2002. Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins. J. Virol. 76:3511-3521.
40. Haas, J., E. C. Park, and B. Seed. 1996. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr. Biol. 6:315-324.
41. Ho, D. D., M. S. Fung, Y. Z. Cao, X. L. Li, C. Sun, T. W. Chang, and N. C. Sun. 1991. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. Proc. Natl. Acad. Sci. USA 88:8949-8952.
42. Ho, D. D., J. A. McKeating, X. L. Li, T. Moudgil, E. S. Daar, N. C. Sun, and J. E. Robinson. 1991. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J. Virol. 65:489-493.
43. Imperiali, B., and K. W. Rickert. 1995. Conformational implications of asparagine-linked glycosylation. Proc. Natl. Acad. Sci. USA 92:97-101.
44. Kasturi, L., H. Chen, and S. H. Shakin-Eshleman. 1997. Regulation of N-linked core glycosylation: use of a site-directed mutagenesis approach to identify Asn-Xaa-Ser/Thr sequons that are poor oligosaccharide acceptors. Biochem. J. 323:415-419.
45. Kessler, J. A., P. M. McKenna, E. A. Emini, C. P. Chan, M. D. Patel, S. K. Gupta, G. E. Mark, C. F. Barbas III, D. R. Burton, and A. J. Conley. 1997. Recombinant human monoclonal antibody IgG1 b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. AIDS Res. Hum. Retrovir. 13:575-581.
46. Kwong, P. D., M. L. Doyle, D. J. Casper, C. Cicala, S. Leavitt, S. Majeed, T. D. Steenbeke, M. Venturi, I. M. Chaiken, M. Fung, H. Katinger, P. W. H. I. Parren, J. Robinson, D. van Ryk, L. Wang, D. R. Burton, E. Freire, R. Wyatt, J. Sodroski, W. A. Hendrickson, and J. Arthos. 2002. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420:678-682.
47. Kwong, P. D., R. Wyatt, S. Majeed, J. Robinson, R. W. Sweet, J. Sodroski, and W. A. Hendrickson. 2000. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure Fold Des. 8:1329-1339.
48. Kwong, P. D., R. Wyatt, J. Robinson, R. W. Sweet, J. Sodroski, and W. A. Hendrickson. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659.
49. Letvin, N. L., D. H. Barouch, and D. C. Montefiori. 2002. Prospects for vaccine protection against HIV-1 infection and AIDS. Annu. Rev. Immunol. 20:73-99.
50. Manivel, V., F. Bayiroglu, Z. Siddiqui, D. M. Salunke, and K. V. Rao. 2002. The primary antibody repertoire represents a linked network of degenerate antigen specificities. J. Immunol. 169:888-897.
51. Manivel, V., N. C. Sahoo, D. M. Salunke, and K. V. Rao. 2000. Maturation of an antibody response is governed by modulations in flexibility of the antigen-combining site. Immunity 13:611-620.
52. Markham, R. B., J. Coberly, A. J. Ruff, D. Hoover, J. Gomez, E. Holt, J. Desormeaux, R. Boulos, T. C. Quinn, and N. A. Halsey. 1994. Maternal IgG1 and IgA antibody to V3 loop consensus sequence and maternal-infant HIV-1 tranmission. Lancet 343:390-391.
53. Mascola, J. R., S. Schlesinger Frankel, and K. Broliden. 2000. HIV-1 entry at the mucosal surface: role of antibodies in protection. AIDS 14(Suppl. 3):S167-S174.
54. Mascola, J. R., S. W. Snyder, O. S. Weislow, S. M. Belay, R. B. Belshe, D. H. Schwartz, M. L. Clements, R. Dolin, B. S. Graham, G. J. Gorse, M. C. Keefer, M. J. McElrath, M. C. Walker, K. F. Wagner, J. G. McNeil, F. E. McCutchan, and D. S. Burke. 1996. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J. Infect. Dis. 173:340-348.
55. McKeating, J. A., C. Shotton, S. Jeffs, C. Palmer, A. Hammond, J. Lewis, K. Oliver, J. May, and P. Balfe. 1996. Immunogenicity of full length and truncated forms of the human immunodeficiency virus type I envelope glycoprotein. Immunol. Lett. 51:101-105.
56. McKeating, J. A., M. Thali, C. Furman, S. Karwowska, M. K. Gorny, J. Cordell, S. Zolla-Pazner, J. Sodroski, and R. A. Weiss. 1992. Amino acid residues of the human immunodeficiency virus type 1 gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction. Virology 190:134-142.
57. Mellquist, J. L., L. Kasturi, S. L. Spitalnik, and S. H. Shakin-Eshleman. 1998. The amino acid following an Asn-X-Ser/Thr sequon is an important determinant of N-linked core glycosylation efficiency. Biochemistry 37:6833-6837.
58. Mian, I. S., A. R. Bradwell, and A. J. Olson. 1991. Structure, function, and properties of antibody binding sites. J. Mol. Biol. 217:133-151.
59. Montefiori, D. C., B. S. Graham, J. Zhou, D. H. Schwartz, L. A. Cavacini, and M. R. Posner. 1993. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. J. Clin. Investig. 92:840-847.
60. Moore, J. P., and D. D. Ho. 1993. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J. Virol. 67:863-875.
61. Moore, J. P., and D. D. Ho. 1995. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS 9(Suppl. A):S117-S136.
62. Moore, J. P., F. E. McCutchan, S. W. Poon, J. Mascola, J. Liu, Y. Cao, and D. D. Ho. 1994. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J. Virol. 68:8350-8364.
63. Moore, J. P., Q. J. Sattentau, R. Wyatt, and J. Sodroski. 1994. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. J. Virol. 68:469-484.
64. Moore, J. P., and J. Sodroski. 1996. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J. Virol. 70:1863-1872.
65. Moore, J. P., A. Trkola, B. Korber, L. J. Boots, J. A. I. Kessler, F. E. McCutchan, J. Mascola, D. D. Ho, J. Robinson, and A. J. Conley. 1995. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J. Virol. 69:122-130.
66. Moore, J. P., R. L. Willey, G. K. Lewis, J. Robinson, and J. Sodroski. 1994. Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1. J. Virol. 68:6836-6847.
67. Myszka, D. G., R. W. Sweet, P. Hensley, M. Brigham-Burke, P. D. Kwong, W. A. Hendrickson, R. Wyatt, J. Sodroski, and M. L. Doyle. 2000. Energetics of the HIV gp120-CD4 binding reaction. Proc. Natl. Acad. Sci. USA 97:9026-9031.
68. Nabel, G. J., and N. J. Sullivan. 2000. Antibodies and resistance to natural HIV infection. N. Engl. J. Med. 343:1263-1265.
69. Nair, D. T., K. Singh, Z. Siddiqui, B. P. Nayak, K. V. Rao, and D. M. Salunke. 2002. Epitope recognition by diverse antibodies suggests conformational convergence in an antibody response. J. Immunol. 168:2371-2382.
70. Nara, P. L., R. R. Garrity, and J. Goudsmit. 1991. Neutralization of HIV-1: a paradox of humoral proportions. FASEB J. 5:2437-2455.
71. Niedrig, M., H. P. Harthus, J. Hinkula, M. Broker, H. Bickhard, G. Pauli, H. R. Gelderblom, and B. Wahren. 1992. Inhibition of viral replication by monoclonal antibodies directed against human immunodeficiency virus gp120. J. Gen. Virol. 73:2451-2455.
72. O'Connor, S. E., and B. Imperiali. 1996. Modulation of protein structure and function by asparagine-linked glycosylation. Chem. Biol. 3:803-812.
73. Overbaugh, J., and L. M. Rudensey. 1992. Alterations in potential sites for glycosylation predominate during evolution of the simian immunodeficiency virus envelope gene in macaques. J. Virol. 66:5937-5948.
74. Pantophlet, R., L. Brade, L. Dijkshoorn, and H. Brade. 1998. Specificity of rabbit antisera against lipopolysaccharide of Acinetobacter. J. Clin. Microbiol. 36:1245-1250.
75. Pantophlet, R., E. O. Saphire, P. Poignard, P. W. H. I. Parren, I. A. Wilson, and D. R. Burton. 2003. Fine mapping of the interaction of neutralizing and non-neutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J. Virol. 77:642-658.
76. Parren, P. W. H. I., I. Mondor, D. Naniche, H. J. Ditzel, P. J. Klasse, D. R. Burton, and Q. J. Sattentau. 1998. Neutralization of HIV-1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J. Virol. 72:3512-3519.
77. Parren, P. W. H. I., J. P. Moore, D. R. Burton, and Q. J. Sattentau. 1999. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS 13(Suppl. A):S137-S162.
78. Poignard, P., T. Fouts, D. Naniche, J. P. Moore, and Q. J. Sattentau. 1996. Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation. J. Exp. Med. 183:473-484.
79. Poignard, P., E. O. Saphire, P. W. H. I. Parren, and D. R. Burton. 2001. GP120: biologic aspects of structural features. Annu. Rev. Immunol. 19:253-274.
80. Posner, M. R., L. A. Cavacini, C. L. Emes, J. Power, and R. Byrn. 1993. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 6:7-14.
81. Posner, M. R., H. S. Elboim, T. Cannon, L. Cavacini, and T. Hideshima. 1992. Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis. AIDS Res. Hum. Retrovir. 8:553-558.
82. Quiñones-Kochs, M. I., L. Buonocore, and J. K. Rose. 2002. Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. J. Virol. 76:4199-4211.
83. Reitter, J. N., R. E. Means, and R. C. Desrosiers. 1998. A role for carbohydrates in immune evasion in AIDS. Nat. Med. 4:679-684.
84. Rini, J. M., R. L. Stanfield, E. A. Stura, P. A. Salinas, A. T. Profy, and I. A. Wilson. 1993. Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen. Proc. Natl. Acad. Sci. USA 90:6325-6329.
85. Rizzuto, C. D., R. Wyatt, N. Hernandez-Ramos, Y. Sun, P. D. Kwong, W. A. Hendrickson, and J. Sodroski. 1998. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280:1949-1953.
86. Roben, P., J. P. Moore, M. Thali, J. Sodroski, C. F. Barbas III, and D. R. Burton. 1994. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68:4821-4828.
87. Robinson, J. E., D. Holton, S. Pacheco-Morell, J. Liu, and H. McMurdo. 1990. Identification of conserved and variant epitopes of human immunodeficiency virus type 1 (HIV-1) gp120 by human monoclonal antibodies produced by EBV-transformed cell lines. AIDS Res. Hum. Retrovir. 6:567-579.
88. Robinson, J. E., H. Yoshiyama, D. Holton, S. Elliott, and D. D. Ho. 1992. Distinct antigenic sites on HIV gp120 identified by a panel of human monoclonal antibodies. J. Cell. Biochem. 50(Suppl. 16E):71.
89. Rossio, J. L., M. T. Esser, K. Suryanarayana, D. K. Schneider, J. W. Bess, Jr., G. M. Vasquez, T. A. Wiltrout, E. Chertova, M. K. Grimes, Q. Sattentau, L. O. Arthur, L. E. Henderson, and J. D. Lifson. 1998. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J. Virol. 72:7992-8001.
90. Sanders, R. W., L. Schiffner, A. Master, F. Kajumo, Y. Guo, T. Dragic, J. P. Moore, and J. M. Binley. 2000. Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits. J. Virol. 74:5091-5100.
91. Sattentau, Q. J., and J. P. Moore. 1995. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 182:185-196.
92. Sattentau, Q. J., M. Moulard, B. Brivet, F. Botto, J. C. Cuillemot, I. Mondor, P. Poignard, and S. Ugolini. 1999. Antibody neutralization of HIV-1 and the potential for vaccine design. Immunol. Lett. 66:143-149.
93. Sayle, R. A., and E. J. Milner-White. 1995. RASMOL: biomolecular graphics for all. Trends Biochem. Sci. 20:374-376.
94. Scanlan, C. N., R. Pantophlet, M. R. Wormwald, E. O. Saphire, R. Stanfield, I. A. Wilson, H. Katinger, R. A. Dwek, P. M. Rudd, and D. R. Burton. 2002. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1→2 mannose residues on the outer face of gp120. J. Virol. 76:7306-7321.
95. Schønning, K., B. Jansson, S. Olofsson, and J. E. S. Hansen. 1996. Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1. J. Gen. Virol. 77:753-758.
96. Schønning, K., O. Lund, O. S. Lund, and J. E. S. Hanssen. 1999. Stochiometry of monoclonal antibody neutralization of T-cell-line-adapted human immunodeficiency virus type 1. J. Virol. 73:8364-8370.
97. Schreiber, M., H. Petersen, C. Wachsmuth, H. Müller, F. T. Hufert, and H. Schmitz. 1994. Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum. J. Virol. 68:3908-3916.
98. MN strain. Proc. Natl. Acad. Sci. USA 87:8597-8601.
99. Shakin-Eshleman, S. H., S. L. Spitalnik, and L. Kasturi. 1996. The amino acid at the X position of an Asn-X-Ser sequon is an important determinant of N-linked core-glycosylation efficiency. J. Biol. Chem. 271:6363-6366.
100. Slagle, S. P., R. E. Kozack, and S. Subramaniam. 1994. Role of electrostatics in antibody-antigen association: anti-hen egg lysozyme/lysozyme complex (HyHEL-5/HEL). J. Biomol. Struct. Dyn. 12:439-456.
101. Spear, G. T., D. M. Takefman, S. Sharpe, M. Ghassemi, and S. Zolla-Pazner. 1994. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding and neutralization. Virology 204:609-615.
102. Stamatatos, L., and C. Cheng-Mayer. 1998. An envelope modification that renders a primary neutralization resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades. J. Virol. 72:7840-7845.
103. Stanfield, R. L., T. M. Fiester, R. A. Lerner, and I. A. Wilson. 1990. Crystal structures of an antibody to a peptide and its complex with peptide antigen at 2.8 Å. Science 248:712-719.
104. Sullivan, N., M. Thali, C. Furman, D. D. Ho, and J. Sodroski. 1993. Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. J. Virol. 67:3674-3679.
105. Thali, M., C. Furman, D. D. Ho, J. Robinson, S. Tilley, A. Pinter, and J. Sodroski. 1992. Discontinuous, conserved neutralization epitopes overlapping the CD4 binding region of the HIV-1 gp120 envelope glycoprotein. J. Virol. 66:5635-5641.
106. Thali, M., J. P. Moore, C. Furman, M. Charles, D. D. Ho, J. Robinson, and J. Sodroski. 1993. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67:3978-3988.
107. Thali, M., U. Olshevshy, C. Furman, D. Gabuzda, M. Posner, and J. Sodroski. 1991. Characterization of a discontinuous human immunodeficiency virus type 1 gp120-epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J. Virol. 65:6188-6193.
108. Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, K. Srinivasan, J. Sodroski, J. P. Moore, and H. Katinger. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100-1108.
109. Tsumoto, K., K. Ogasahara, Y. Ueda, K. Watanabe, K. Yutani, and I. Kumagai. 1996. Role of salt bridge formation in antigen-antibody interaction. Entropic contribution to the complex between hen egg white lysozyme and its monoclonal antibody HyHEL10. J. Biol. Chem. 271:32612-32616.
110. Tsumoto, K., Y. Ueda, K. Maenaka, K. Watanabe, K. Ogasahara, K. Yutani, and I. Kumagai. 1994. Contribution to antibody-antigen interaction of structurally perturbed antigenic residues upon antibody binding. J. Biol. Chem. 269:28777-28782.
111. Vinogradov, E. V., R. Pantophlet, L. Dijkshoorn, L. Brade, O. Hoist, and H. Brade. 1996. Structural and serological characterisation of two O-specific polysaccharides of Acinetobacter. Eur. J. Biochem. 239:602-610.
112. MN multiple antigenic peptides. J. Immunol. 153:1895-1904.
113. Wilson, I. A., and L. K. Jolliffe. 1999. The structure, organization, activation, and plasticity of the erythropoietin receptor. Curr. Opin. Struct. Biol. 9:696-704.
114. Wormald, M. R., and R. A. Dwek. 1999. Glycoproteins: glycan presentation and protein-fold stability. Struct. Fold Des. 7:R155-R160.
115. Wyatt, R., P. D. Kwong, E. Desjardins, R. W. Sweet, J. Robinson, W. A. Hendrickson, and J. G. Sodroski. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705-711.
116. Wyatt, R., J. Moore, M. Accola, E. Desjardin, J. Robinson, and J. Sodroski. 1995. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 69:5723-5733.
117. Wyatt, R., and J. Sodroski. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280:1884-1888.
118. Yang, X., M. Farzan, R. Wyatt, and J. Sodroski. 2000. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins. J. Virol. 74:5716-5725.
119. Yang, X., L. Florin, M. Farzan, P. Kolchinsky, P. D. Kwong, J. Sodroski, and R. Wyatt. 2000. Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution. J. Virol. 74:4746-4754.
120. Yang, X., J. Lee, E. M. Mahony, P. D. Kwong, R. Wyatt, and J. Sodroski. 2002. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J. Virol. 76:4634-4642.
121. Yoshiyama, H., H. Mo, J. P. Moore, and D. D. Ho. 1994. Characterization of mutants of human immunodeficiency virus type 1 that have escaped neutralization by a monoclonal antibody to the gp120 V2 loop. J. Virol. 68:974-978.
122. Zhu, X., C. Borchers, R. J. Bienstock, and K. B. Tomer. 2000. Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry 39:11194-11204.